PMC Articles for MedGen (Select 75873) - PMC

Links from MedGen

Items: 1 to 20 of 40

<< First< Prev

Page of 2

Select item 23599261.

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group

S Pignata, G Scambia, C Pisano, E Breda, M Di Maio, S Greggi, G Ferrandina, D Lorusso, V Zagonel, A Febbraro, N Riva, V De Rosa, C Gallo, F Perrone

Br J Cancer. 2007 Jun 4; 96(11): 1639–1643. Published online 2007 May 8. doi: 10.1038/sj.bjc.6603787

PMCID:: PMC2359926

Abstract Article PDF–86K

Select item 36137922.

Typical and atypical metastatic sites of recurrent endometrial carcinoma

Vikram Kurra, Katherine M. Krajewski, Jyothi Jagannathan, Angela Giardino, Suzanne Berlin, Nikhil Ramaiya

Cancer Imaging. 2013; 13(1): 113–122. Published online 2013 Mar 26. doi: 10.1102/1470-7330.2013.0011

PMCID:: PMC3613792

Abstract Article PDF–824K

Select item 36947163.

Treatment of Advanced or Recurrent Endometrial Carcinoma with Doxorubicin in Patients Progressing after Paclitaxel/Carboplatin: Memorial Sloan-Kettering Cancer Center (MSKCC) Experience from 1995-2009

Vicky Makker, Martee L. Hensley, Qin Zhou, Alexia Iasonos, Carol. A. Aghajanian

Int J Gynecol Cancer. Author manuscript; available in PMC 2013 Jun 27.

Published in final edited form as: Int J Gynecol Cancer. 2013 Jun; 23(5): 929–934. doi: 10.1097/IGC.0b013e3182915c20

PMCID:: PMC3694716

Abstract Article PDF–111K

Select item 39249104.

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Kristina Lindemann, Susanne Malander, Rene D Christensen, Mansoor R Mirza, Gunnar B Kristensen, Elisabeth Aavall-Lundqvist, Ignace Vergote, Per Rosenberg, Karin Boman, Britta Nordstrøm

BMC Cancer. 2014; 14: 68. Published online 2014 Feb 5. doi: 10.1186/1471-2407-14-68

PMCID:: PMC3924910

Abstract Article PDF–422K

Select item 32280285.

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

J. Alejandro Rauh-Hain, Marcela G. del Carmen

Oncologist. 2010 Aug; 15(8): 852–861. Published online 2010 Jul 21. doi: 10.1634/theoncologist.2010-0091

PMCID:: PMC3228028

Abstract Article PDF–89K

Select item 43486386.

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma

Brian M. Slomovitz, Yunyun Jiang, Melinda S. Yates, Pamela T. Soliman, Taren Johnston, Maureen Nowakowski, Charles Levenback, Qian Zhang, Kari Ring, Mark F. Munsell, David M. Gershenson, Karen H. Lu, Robert L. Coleman

J Clin Oncol. 2015 Mar 10; 33(8): 930–936. Published online 2015 Jan 26. doi: 10.1200/JCO.2014.58.3401

PMCID:: PMC4348638

Abstract Article PDF–156K

Select item 30648917.

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Yutaka Ueda, Takahito Miyake, Tomomi Egawa-Takata, Takashi Miyatake, Shinya Matsuzaki, Takuhei Yokoyama, Kiyoshi Yoshino, Masami Fujita, Takayuki Enomoto, Tadashi Kimura

Cancer Chemother Pharmacol. 2011; 67(4): 829–835. Published online 2010 Jun 20. doi: 10.1007/s00280-010-1384-z

PMCID:: PMC3064891

Abstract Article PDF–199K

Select item 113472288.

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design

Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog, David Cibula, Nicoletta Colombo, Bhavana Pothuri, Jalid Sehouli, Jacob Korach, Joyce Barlin, Christos A Papadimitriou, Toon van Gorp, Debra Richardson, Michael McCarthy, Yoland Antill, Mansoor Raza Mirza, Kai Li, Pratheek Kalyanapu, Brian Slomovitz, Robert L Coleman

Int J Gynecol Cancer. 2024 Aug; 34(8): 1283–1289. Published online 2024 Apr 16. doi: 10.1136/ijgc-2024-005412

PMCID:: PMC11347228

Abstract Article PDF–1.2M

Select item 51207309.

A Phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, everolimus, in patients with recurrent endometrial carcinoma

Brian M. Slomovitz, Karen H. Lu, Taren Johnston, Robert L. Coleman, Mark Munsell, Russell R. Broaddus, Cheryl Walker, Lois M. Ramondetta, Thomas W. Burke, David M. Gershenson, Judith Wolf

Cancer. Author manuscript; available in PMC 2016 Nov 23.

Published in final edited form as: Cancer. 2010 Dec 1; 116(23): 5415–5419. Published online 2010 Aug 2. doi: 10.1002/cncr.25515

PMCID:: PMC5120730

Abstract Article PDF–310K

Select item 521961210.

Long-term survival after anterior pelvic exenteration and total vaginectomy for recurrent endometrial carcinoma with metastatic inguinal nodes at the time of surgery

Benjamin Margolis, Sun Woo Kim, Dennis S. Chi

Gynecol Oncol Rep. 2017 Feb; 19: 39–41. Published online 2016 Dec 29. doi: 10.1016/j.gore.2016.12.007

PMCID:: PMC5219612

Abstract Article PDF–169K

Select item 529448511.

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

P-E Heudel, M Fabbro, C Roemer-Becuwe, M C Kaminsky, A Arnaud, F Joly, S Roche-Forestier, J Meunier, C Foa, B You, F Priou, Y Tazi, A Floquet, F Selle, D Berton-Rigaud, A Lesoin, E Kalbacher, A Lortholary, L Favier, I Treilleux, I Ray-Coquard

Br J Cancer. 2017 Jan 31; 116(3): 303–309. Published online 2017 Jan 10. doi: 10.1038/bjc.2016.430

PMCID:: PMC5294485

Abstract Article PDF–311K

Select item 695147812.

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael Frumovitz, Samir N. Khleif, Warner K. Huh, Michael J. Birrer

Gynecol Oncol Rep. 2020 Feb; 31: 100532. Published online 2020 Jan 2. doi: 10.1016/j.gore.2019.100532

Correction in:: Gynecol Oncol Rep. 2020 Aug; 33: 100590.

PMCID:: PMC6951478

Abstract Article PDF–366K

Select item 704962713.

Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review

Akihiro Takeda, Wataru Koike, Kazuko Watanabe

Gynecol Oncol Rep. 2020 May; 32: 100553. Published online 2020 Feb 20. doi: 10.1016/j.gore.2020.100553

PMCID:: PMC7049627

Abstract Article PDF–975K

Select item 831994814.

NON-EXENTERATIVE SURGICAL MANAGEMENT OF RECURRENT ENDOMETRIAL CARCINOMA

Lea A Moukarzel, Kenya F. Braxton, Quin C. Zhou, Silvana Pedra Nobre, Alexia Iasonos, Kaled M. Alektiar, William P. Tew, Nadeem R. Abu-Rustum, Mario M. Leitao, Jr., Dennis S. Chi, Jennifer J. Mueller

Gynecol Oncol. Author manuscript; available in PMC 2022 Aug 1.

Published in final edited form as: Gynecol Oncol. 2021 Aug; 162(2): 268–276. Published online 2021 Jun 2. doi: 10.1016/j.ygyno.2021.05.020

PMCID:: PMC8319948

Abstract Article PDF–260K

Select item 1071120015.

Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma

Joyce M. Cheng, Stephanie Gaillard, Anna L. Beavis, Tullia Rushton, Amanda N. Fader

Front Oncol. 2023; 13: 1249370. Published online 2023 Nov 27. doi: 10.3389/fonc.2023.1249370

PMCID:: PMC10711200

Abstract Article PDF–2.2M

Select item 1033524516.

Recurrent endometrial carcinoma metastasis to the temporal bone and skull base

BLK Wong, AB Addison, CE Swords, S Patil

Ann R Coll Surg Engl. 2021 Nov; 103(10): e338–e340. doi: 10.1308/rcsann.2021.0055

PMCID:: PMC10335245

Abstract Article PDF–172K

Select item 1030724017.

Retracted: Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Evidence-Based Complementary and Alternative Medicine

Evid Based Complement Alternat Med. 2023; 2023: 9850950. Published online 2023 Jun 21. doi: 10.1155/2023/9850950

Retracts:: Evid Based Complement Alternat Med. 2021; 2021: 8793187.

PMCID:: PMC10307240

Retraction PDF–115K

Select item 1001768018.

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C. Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie Lheureux

Nat Commun. 2023; 14: 1452. Published online 2023 Mar 15. doi: 10.1038/s41467-023-37084-w

PMCID:: PMC10017680

Abstract Article PDF–1.1M

Select item 854557619.

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Yi Li, Dong Yang, Shuangjian Yang

Evid Based Complement Alternat Med. 2021; 2021: 8793187. Published online 2021 Oct 18. doi: 10.1155/2021/8793187

Retraction in:: Evid Based Complement Alternat Med. 2023; 2023: 9850950.

PMCID:: PMC8545576

Abstract Article

Select item 745261720.

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]

Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Roisin O'Cearbhaill, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael J. Birrer

Gynecol Oncol Rep. 2020 Aug; 33: 100590. Published online 2020 May 28. doi: 10.1016/j.gore.2020.100590

Corrects:: Gynecol Oncol Rep. 2020 Feb; 31: 100532.

PMCID:: PMC7452617

Correction PDF–126K

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from MedGen

Items: 1 to 20 of 40

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity